Holen Sie sich die Stockscreener-App
12.16
2.81%
0.2963
Schlusskurs vom Vortag:
$11.86
Offen:
$11.94
24-Stunden-Volumen:
859.15K
Relative Volume:
0.39
Marktkapitalisierung:
$828.18M
Einnahmen:
$2.73B
Nettoeinkommen (Verlust:
$-1.13B
KGV:
-0.7296
EPS:
-16.6622
Netto-Cashflow:
$-83.00M
1W Leistung:
+7.15%
1M Leistung:
+5.21%
6M Leistung:
-55.66%
1J Leistung:
-59.00%
1-Tages-Spanne:
$11.69
$12.37
1-Wochen-Bereich:
$11.12
$12.74
52-Wochen-Spanne:
$9.92
$35.58
Quidelortho Corp Stock (QDEL) Company Profile
Firmenname
Quidelortho Corp
Sektor
Branche
Telefon
(858) 552-1100
Adresse
9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA
Compare QDEL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QDEL
Quidelortho Corp
|
12.14 | 808.75M | 2.73B | -1.13B | -83.00M | -16.66 |
ABT
Abbott Laboratories
|
86.65 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.23 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.82 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.81 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.73 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Quidelortho Corp Stock (QDEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-08 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-10 | Eingeleitet | Jefferies | Hold |
| 2024-09-19 | Fortgesetzt | UBS | Neutral |
| 2024-09-05 | Hochstufung | Craig Hallum | Hold → Buy |
| 2024-03-04 | Herabstufung | UBS | Neutral → Sell |
| 2024-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-14 | Hochstufung | UBS | Sell → Neutral |
| 2022-09-19 | Eingeleitet | Citigroup | Neutral |
| 2022-07-20 | Eingeleitet | UBS | Sell |
| 2022-06-17 | Fortgesetzt | JP Morgan | Neutral |
| 2022-02-22 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-01-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-26 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Strong Buy |
| 2018-03-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-01-22 | Bestätigt | Barclays | Overweight |
| 2018-01-04 | Hochstufung | CL King | Neutral → Buy |
| 2017-09-19 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-07-18 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-07-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2017-04-25 | Bestätigt | Canaccord Genuity | Hold |
| 2017-02-17 | Eingeleitet | CL King | Neutral |
| 2016-12-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-06-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-02-18 | Bestätigt | Barclays | Overweight |
| 2016-02-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2016-01-08 | Bestätigt | Canaccord Genuity | Buy |
| 2015-12-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-09-02 | Eingeleitet | Barclays | Overweight |
| 2013-07-31 | Bestätigt | Canaccord Genuity | Buy |
| 2011-03-03 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Quidelortho Corp Aktie (QDEL) Neueste Nachrichten
QuidelOrtho Corp (QDEL) Stock Down 4.2% -- Now Undervalued? GF S - GuruFocus
How Quidelortho Corp Com (QDEL) Affects Rotational Strategy Timing - Stock Traders Daily
When Blood Compatibility Becomes a Pregnancy Risk – Company Announcement - Financial Times
QuidelOrtho stock (US7476011036): Shares rise after latest market move - AD HOC NEWS
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences - Yahoo Finance
QuidelOrtho (QDEL) price target decreased by 34.46% to 19.25 - MSN
QuidelOrtho stock (US7476011036): Shares fall after recent after-hours pressure - AD HOC NEWS
QuidelOrtho Corp stock (US7476011036): analysts divided as short interest climbs and sentiment weake - AD HOC NEWS
5 Insightful Analyst Questions From QuidelOrtho’s Q1 Earnings Call - Yahoo Finance
QuidelOrtho Corp (QDEL) Shares Surge 3.0% -- What GF Score of 48 Tells Investors - GuruFocus
QuidelOrtho stock (US7476011036): Q1 loss narrows as shares stay under pressure - AD HOC NEWS
QuidelOrtho stock sinks to 52-week lowhere's why - MSN
QuidelOrtho: A Growing, Stable Business With A Significant Mispricing (NASDAQ:QDEL) - Seeking Alpha
QuidelOrtho (QDEL) Q1 2026 Earnings Transcript - AOL.com
QuidelOrtho (NASDAQ:QDEL) misses Q1 CY2026 revenue estimates - MSN
Deckers, Franklin, Eaton, Coupang, QuidelOrtho Trending Among Analysts - TipRanks
QuidelOrtho Corporation 2026 Q1ResultsEarnings Call Presentation (NASDAQ:QDEL) 2026-05-08 - Seeking Alpha
QuidelOrtho Corp stock (US7476011036): Q1 2026 loss widens as respiratory sales weaken - AD HOC NEWS
Pregnancy Detection Kits Market Analysis Report 2026 - GlobeNewswire Inc.
QuidelOrtho Is Maintained at Neutral by Citigroup - Moomoo
QuidelOrtho (QDEL) reports Q1 loss, tops revenue estimates - MSN
QuidelOrtho price target lowered to $12 from $17 at UBS - TipRanks
QuidelOrtho downgraded to Hold from Buy at Jefferies - TipRanks
UBS Adjusts Price Target on QuidelOrtho to $12 From $17, Maintains Neutral Rating - marketscreener.com
Jefferies Maintains QuidelOrtho(QDEL.US) With Hold Rating, Maintains Target Price $12.5 - Moomoo
Jefferies Downgrades QuidelOrtho to Hold From Buy, Adjusts Price Target to $12.50 From $35 - marketscreener.com
QuidelOrtho reports GAAP net loss of USD 92M in Q1 2026 - Medical Buyer
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Contineum Therapeutics, Inc. Class A (CTNM) and Schrodinger (SDGR) - The Globe and Mail
QuidelOrtho (QDEL) Loss Deepens In Q1 As Long Trailing Losses Challenge Bullish Narratives - simplywall.st
QDEL SEC FilingsQuidel 10-K, 10-Q, 8-K Forms - Stock Titan
QuidelOrtho Balances Near-Term Strain With Recovery Plan - TipRanks
QUIDELORTHO Corporation Q1 2026 SEC 10-Q Filing: Financial Results, Risk Factors, and Management Discussion - Minichart
Invesco Ltd. reports 4.6% stake in QuidelOrtho (NASDAQ: QDEL) - Stock Titan
Newtyn Management (NASDAQ: QDEL) reports 4.56M shares, 6.7% holding - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
William Blair Maintains QuidelOrtho(QDEL.US) With Hold Rating, Announces Target Price $11.66 - Moomoo
QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2026 Earnings Call Transcript - Insider Monkey
QuidelOrtho forecasts $2.7B-$2.75B 2026 revenue while targeting $100M-$120M free cash flow amid China pricing uncertainty - MSN
QuidelOrtho : Quarterly Report for Quarter Ending March 29, 2026 (Form 10-Q) - marketscreener.com
QDEL Q1 Deep Dive: Softer Respiratory Demand and China Headwinds Drive Guidance Reset - The Globe and Mail
QuidelOrtho Q1 2026 slides: revenue falls 13%, respiratory weakness pressures margins - Investing.com Nigeria
QuidelOrtho Q1 Earnings Call Highlights - Yahoo Finance
QuidelOrtho Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: QuidelOrtho Q1 2026 results miss expectations - Investing.com UK
QuidelOrtho Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: QuidelOrtho Q1 2026 results miss expectations By Investing.com - Investing.com Nigeria
QuidelOrtho (QDEL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
QuidelOrtho (NASDAQ: QDEL) posts Q1 2026 loss as revenue declines 11% - Stock Titan
Q1 2026 QuidelOrtho Corp Earnings Call Transcript - GuruFocus
Finanzdaten der Quidelortho Corp-Aktie (QDEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quidelortho Corp-Aktie (QDEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Busky Joseph M. | Chief Financial Officer |
Feb 13 '26 |
Buy |
23.66 |
3,370 |
79,742 |
10,290 |
| Blaser Brian J. | President and CEO |
Feb 13 '26 |
Buy |
23.59 |
10,540 |
248,661 |
40,073 |
| RHOADS ANN D | Director |
Dec 10 '25 |
Buy |
28.27 |
750 |
21,206 |
15,021 |
| Wilkins Joseph D Jr. | Director |
Nov 26 '25 |
Buy |
27.95 |
370 |
10,343 |
11,876 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Option Exercise |
15.74 |
7,021 |
110,511 |
41,087 |
| WIDDER KENNETH J | Director |
Nov 25 '25 |
Sale |
27.81 |
4,026 |
111,965 |
37,061 |
0.32%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):